India to United Kingdom: Anastrozole Export Trade Route

To import licensed medicinal products into the UK, the following authorizations are mandatory:

1. Wholesale Distribution Authorisation (WDA(H)): This license permits the wholesale distribution of medicinal products within the UK.

2. Manufacturer's Licence: Required for entities involved in the manufacturing or importation of medicinal products.

3. Marketing Authorisation (MA): Also known as a product license, this authorization is necessary before a medicinal product can be marketed in the UK.

The application process for these licenses involves submitting comprehensive dossiers, typically in the Common Technical Document (CTD) or electronic CTD (eCTD) format. The approval timelines and associated fees vary depending on the complexity of the application and the specific product. Detailed guidance on the application process and fees is available through the MHRA.

Additionally, the MHRA conducts inspections of manufacturing sites to ensure compliance with Good Manufacturing Practice (GMP) standards. Indian manufacturing facilities exporting to the UK must undergo these inspections to verify adherence to GMP requirements. The MHRA maintains a list of GMP-compliant manufacturers, which is accessible for verification purposes.

Indian exporters of Anastrozole formulations must comply with the UK's GMP standards to supply products to the UK market. This compliance is verified through MHRA inspections, resulting in the issuance of GMP certificates. Several Indian facilities have been inspected and approved by the MHRA. For instance, in February 2024, Intas Pharmaceuticals Limited's facility in Dehradun, India, received GMP certification following a successful inspection. Similarly, in January 2024, Sun Pharmaceutical Industries Limited's facility in Dadra, India, was granted GMP certification.

The MHRA's database provides up-to-date information on GMP-compliant manufacturers, including Indian facilities. Regular inspections are conducted to ensure ongoing compliance, and any non-compliance findings are documented and addressed accordingly.

Between 2024 and 2026, several regulatory developments have impacted Indian pharmaceutical exports to the UK:

• January 2025: The MHRA updated its guidance on importing human medicines, emphasizing the necessity for appropriate licenses and compliance with GMP standards. This update clarified the requirements for importing both licensed and unlicensed medicines into the UK.

• November 2025: Piramal Pharma Solutions' facility in Grangemouth, UK, received updated MHRA GMP certificates following a successful compliance report and desktop inspection. This underscores the MHRA's commitment to ensuring GMP compliance through regular assessments.

These developments highlight the MHRA's ongoing efforts to maintain high standards for medicinal products entering the UK market, affecting both domestic and international manufacturers and exporters.

Anastrozole is a non-steroidal aromatase inhibitor primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. The prevalence of breast cancer in the United Kingdom has been increasing, with approximately 55,000 new cases diagnosed annually as of 2024. This rising incidence, coupled with an aging population and advancements in early detection, has led to a growing demand for effective treatments like Anastrozole.

The National Health Service (NHS) provides universal health coverage, ensuring that patients have access to necessary medications. Healthcare spending in the UK has been on an upward trajectory, with expenditures reaching £200 billion in 2024, reflecting a commitment to addressing the healthcare needs of the population.

While the UK has a robust pharmaceutical manufacturing sector, it also relies on imports to meet the demand for certain medications, including Anastrozole formulations. In 2024, the UK imported finished pharmaceutical formulations containing Anastrozole valued at $0.8 million from India alone, indicating a significant reliance on international suppliers to supplement domestic production.

Pharmaceutical products under HS code 30049099, which includes finished formulations containing Anastrozole, are subject to a 0% Most-Favored-Nation (MFN) import duty rate in the United Kingdom. This exemption aligns with the UK's policy to facilitate access to essential medicines.

As of March 2026, there is no Free Trade Agreement (FTA) between India and the United Kingdom that specifically affects pharmaceutical tariffs. Additionally, there are no anti-dumping duties imposed on Anastrozole formulations imported from India.

India is a key supplier of Anastrozole formulations to the United Kingdom, accounting for $0.8 million in imports in 2024. This represents 0.7% of India's total Anastrozole formulation exports, which amounted to $110.7 million.

Other major countries supplying Anastrozole to the UK include Germany and the United States. India's competitive pricing, driven by cost-effective manufacturing processes and economies of scale, often positions it favorably compared to European and American manufacturers. This pricing advantage, combined with the UK's zero-duty policy on pharmaceutical imports, enhances the attractiveness of Indian Anastrozole formulations in the UK market.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume as of 2025. The country's pharmaceutical industry is supported by a vast network of manufacturing facilities, many of which are certified by international regulatory bodies. For instance, as of November 2024, India had 396 facilities registered under the U.S. FDA's Generic Drug User Fee Amendments (GDUFA) program, the highest number globally.

Specific to Anastrozole formulations, Indian manufacturers have established significant production capacities. Companies such as Alembic Pharmaceuticals operate multiple facilities dedicated to finished dosage forms, including tablets and capsules. These facilities are approved by regulatory authorities such as the WHO and the European Medicines Agency (EMA). Additionally, Akums Drugs and Pharmaceuticals has units in Haridwar certified by the European GMP, producing solid oral dosage forms.

India's cost advantages stem from economies of scale, a skilled workforce, and lower operational expenses. These factors enable the production of high-quality Anastrozole formulations at competitive prices, making India a preferred sourcing destination for global buyers.

When comparing Anastrozole formulation exports, India offers a compelling balance of cost and quality. As of December 2024, the average unit price for generic oral solid pharmaceuticals from India was approximately $0.13, compared to $0.19 in the United States and $0.12 in China. This pricing advantage is attributed to India's efficient manufacturing processes and lower production costs.

In terms of quality, Indian pharmaceutical manufacturers adhere to stringent international standards. Facilities producing Anastrozole formulations are often certified by regulatory bodies such as the U.S. FDA, EMA, and WHO. For example, Granules India Limited's facility in Hyderabad received U.S. FDA approval in November 2025, underscoring the industry's commitment to quality.

European manufacturers are known for high-quality branded generics but often at higher price points due to higher operational costs. Chinese manufacturers offer competitive pricing; however, concerns about regulatory compliance and quality consistency have been noted. Therefore, Indian Anastrozole formulations present an optimal combination of affordability and quality assurance for buyers in the United Kingdom.

The India-United Kingdom supply chain for Anastrozole formulations has demonstrated reliability, supported by substantial manufacturing capacities and robust infrastructure. Indian manufacturers have invested in state-of-the-art facilities equipped with advanced packaging and cold chain capabilities to ensure product integrity during transit.

Regulatory compliance is a cornerstone of India's pharmaceutical industry. Manufacturers regularly undergo inspections by international agencies, maintaining certifications such as WHO-GMP and U.S. FDA approvals. For instance, Granules India Limited's Hyderabad facility received U.S. FDA approval in November 2025, reflecting adherence to stringent quality standards.

While no significant supply disruptions have been reported recently, manufacturers continue to expand capacities to meet growing global demand. For example, Alembic Pharmaceuticals has been modernizing and expanding its facilities in Ankleshwar to enhance production capabilities.

For United Kingdom buyers sourcing Anastrozole formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among suppliers. Establish clear agreements on order sizes to align with both parties' logistical and financial considerations.

• Payment Terms: Standard payment terms in India-United Kingdom pharmaceutical trade often include letters of credit or advance payments. Negotiate terms that balance cash flow management with supplier trust.

• Supplier Qualification Process: Conduct thorough due diligence, including audits of manufacturing facilities, verification of regulatory certifications, and assessment of quality control systems to ensure compliance with UK standards.

• Regulatory Compliance: Ensure that selected suppliers have up-to-date approvals from relevant authorities such as the U.S. FDA, EMA, and WHO to guarantee product quality and facilitate smooth importation processes.

By implementing these strategies, buyers can establish a robust and reliable supply chain for Anastrozole formulations from India.

By adhering to this comprehensive framework, United Kingdom companies can effectively qualify Indian suppliers of Anastrozole formulations, ensuring compliance with regulatory standards and safeguarding product quality.